Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin ® Outcomes Registry and Experience
Conclusion
These results suggested that daptomycin at doses >6 mg/kg/day was effective and well tolerated. High-dose daptomycin is a potential therapeutic option in patients with difficult-to-treat Gram-positive infections.
Funding
This study was funded by Novartis Pharma AG.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Cubicin | Drugs & Pharmacology | Endocarditis | Infective Endocarditis | Osteomyelitis | Pharmaceuticals | Skin | Staphylococcus Aureus | Study